Bell International Laboratories, Inc. – FDA 483, Jun 12, 2025
Bell International Laboratories, Inc. in Eagan, MN, was inspected by the FDA from June 2-12, 2025, for OTC drug manufacturing. The inspection revealed significant deficiencies across multiple areas, including raw material identity verification, inadequate investigation of out-of-specification results, and unvalidated manufacturing processes. Furthermore, severe data integrity issues, incomplete batch records, and a deficient supplier qualification program were observed, indicating a lack of robust quality control and adherence to GMP regulations.
ID · c32624ad-c6df-42be-b02e-64f091799f2b
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.